Biocon Ltd, an innovation-led global biopharmaceuticals company, announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India’s (DCGI) approval for an extracorporeal blood purification (EBP) device CytoSorb to reduce pro-inflammatory cytokines levels in confirmed COVID-19 patients admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure. The company […]
Tag: Biocon Biologics-coronavirus
Biocon Ltd. and Biocon Biologics have activated business continuity plans across their functions to meet the needs of patients, partners, customers and other stakeholders who depend on its products. As a global company, it has presence across India, UAE, Malaysia, Singapore, Europe, U.S. and are adjusting all operations to fully comply with regulations issued by […]